Vaccination News Home Page                                            subscribe Vaccination NewsLetter

http://adc.bmjjournals.com/cgi/content/abstract/archdischild%3b88/5/375

Full Text of this Article Reprint (PDF) Version of this Article Email this link to a friend eLetters: Submit a response to this article Similar articles found in: ADC Online PubMed PubMed Citation Search Medline for articles by: Baker, C J || Edwards, M S Alert me when: new articles cite this article   Download to Citation Manager

Collections under which this article appears: Drugs: immunological products and vaccines Children

Archives of Disease in Childhood 2003;88:375-378
© 2003 BMJ Publishing Group & Royal College of Paediatrics and Child Health
 

Group B streptococcal conjugate vaccines

C J Baker and M S Edwards

Section of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA

Correspondence to:
Dr M S Edwards, Baylor College of Medicine, One Baylor Plaza, Room 302A, Houston, Texas 77030, USA;
morvene@bcm.tmc.edu

ABSTRACT
Linkage of bacterial capsular polysaccharides to proteins to create conjugate vaccines has had a dramatic impact on the health of children. Although unconjugated polysaccharides are poorly immunogenic in infants and some older children and adults, their covalent coupling with proteins stimulates T cell dependent antigenic recognition that profoundly enhances immunogenicity. In the decade since the introduction and widespread use of Haemophilus influenzae type b polysaccharide conjugate vaccines in the United States, invasive H influenzae infections have become a rarity in childhood.¹ Similarly, the conjugation of polysaccharides of Streptococcus pneumoniae to a derivative of diphtheria toxoid and the addition of pneumococcal conjugate vaccine to infant immunisation schedules carries with it promise for a similar decline in the incidence of invasive pneumococcal disease in paediatric patients.²

Keywords: vaccine; streptococcus

Abbreviations: CPS, capsular polysaccharide; GBS, group B streptococcus; GMC, geometric mean concentration; IAP, intrapartum antibiotic prophylaxis; TT, tetanus toxoid

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.